Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial

Nature Medicine · Published 2026-07-01 · DOI 10.1038/s41591-026-04491-7

Free full text

Authors (17)

Weiqi Chen, Lingling Jiang, Chunling Duan, Moorim Kang, Jinyi Ye, Ling Wang, Yuesong Pan, Hui Qu, Xiaoling Liao, Xuejiao Zhou, Yichen Li, Zubao Gan, Junnan Chen, Ian Schacht, Robert F. Place, Long-Cheng Li, Yilong Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Chen, W., Jiang, L., Duan, C., et al. (2026). Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04491-7

Related articles

• Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial · Nature Medicine · 2026 · Same journal
• Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial · Nature Medicine · 2026 · Same journal
• FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial · Nature Medicine · 2026 · Same journal
• Data rights are the missing pillar for modernizing consent in medicine · Nature Medicine · 2026 · Same journal
• Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection · Nature Medicine · 2026 · Same journal
• Multi-omics maps human–pig interactions in extracorporeal liver cross-circulation · Nature Medicine · 2026 · Same journal
• The genetic architecture of fibromyalgia across 2.5 million individuals · Nature Medicine · 2026 · Same journal
• Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy · Nature Medicine · 2026 · Same journal
• Early detection of Alzheimer’s disease with circular RNA from blood · Nature Medicine · 2026 · Same journal
• When caution becomes harm · Nature Medicine · 2026 · Same journal